« Return to News | Awards & Advancement

CRI Lifetree appoints Craig-Rodriguez and Marcos to leadership team

Friday, September 28, 2012 02:59 PM

CRI Lifetree, a multi-therapeutic early stage research company, has strengthened its early phase leadership with the appointments of Alicia Craig-Rodriguez as chief operating officer and Jose Marcos as East Coast director of clinical operations. 

Craig-Rodriguez has more than 25 years of leadership experience, including 15 years of overseeing the operational, regulatory and quality compliance of more than 1,000 clinical trials. She has led teams in the creation of comprehensive and industry-compliant SOPs, quality management programs and employee training. Prior to joining CRI Lifetree, Craig-Rodriguez served as president of Comprehensive Clinical Development.

Marcos will add 18 years of experience in hands-on phase I expertise to CRI Lifetree’s leadership team. Prior to joining CRI Lifetree, Marcos served as vice president of phase I clinical operations at Comprehensive Clinical Development. During his tenure there, Marcos advanced the operating infrastructure from a single, 36-bed unit to include three state-of-the-art facilities with a bed capacity exceeding 400 beds.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.